<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999413</url>
  </required_header>
  <id_info>
    <org_study_id>FAMYLY</org_study_id>
    <nct_id>NCT01999413</nct_id>
  </id_info>
  <brief_title>Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients</brief_title>
  <acronym>FAMYLY</acronym>
  <official_title>Pilot Study of the Efficacy and Tolerance of the Adjunction of a Fish Oil Emulsion to Daunorubicin and Cytarabine Chemotherapy for the Treatment of Acute MYeloblastic Leukemia of Younger Patients With High-risk Cytogenetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study of the efficacy and tolerance of the adjunction of a Fish oil emulsion to
      daunorubicin and cytarabine chemotherapy for the treatment of Acute MYeloblastic Leukemia of
      Younger patients (under 61 years) with high-risk cytogenetics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjunction of a Fish oil emulsion OMEGAVEN to daunorubicin and cytarabine chemotherapy for
      the treatment of Acute MYeloblastic Leukemia of Younger patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response to study treatment</measure>
    <time_frame>1 month</time_frame>
    <description>Number of patients incomplete response rate after the adjunction of a Fish oil emulsion to daunorubicin and cytarabine chemotherapy for the induction of untreated AML</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>4 months</time_frame>
    <description>Number of patients with side effects during and after the admistration of a Fish oil emulsion with daunorubicin and cytarabine chemotherapy for the induction of untreated AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy on peripheral blasts decrease</measure>
    <time_frame>1 month</time_frame>
    <description>Daily quantification of peripheral blasts by flow cytometry during the adjunction of a Fish oil emulsion to daunorubicin and cytarabine chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>1 month</time_frame>
    <description>Measure of plasma concentration of daunorubicin and cytarabine administered together with a fish oil emulsion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>OMEGAVEN - Daunorubicin - Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If WBC ≥ 30 G/L, chemotherapy the induction cycle :
Daunorubicin 60 mg/m²/day IV on D1, D2, and D3
Cytarabine 200 mg/m²/day D1 to D7
OMEGAVEN® 2 ml/kg D1 to D9,
If WBC ≤ 30 G/L, OMEGAVEN during 48 hours
Induction cycle :
OMEGAVEN® 2 ml/kg D-2 to D7 Daunorubicin 60 mg/m²/day IV on D1, D2, and D3
- Cytarabine 200 mg/m²/day IV D1 to D7
bone marrow aspirate at D15: If BM blasts are &gt; 5% or if second induction course :
Daunorubicin 35 mg/m²/day IV D17 and D18
OMEGAVEN® 2 ml/kg
Cytarabine 1000 mg/m²/12h IV on D17, D18, and D19
For all patients: G-CSF 5 µg/kg/day subcutaneously from D21 to hematopoietic recovery (PMN &gt; 1 G/L or &gt; 0.5 G/L during 3 days).
Consolidation will be administered at investigator's discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMEGAVEN</intervention_name>
    <description>AML Study treatment induction phase</description>
    <arm_group_label>OMEGAVEN - Daunorubicin - Cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>AML Study treatment induction phase</description>
    <arm_group_label>OMEGAVEN - Daunorubicin - Cytarabine</arm_group_label>
    <other_name>Cerubidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>AML Study treatment induction phase</description>
    <arm_group_label>OMEGAVEN - Daunorubicin - Cytarabine</arm_group_label>
    <other_name>Aracytine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient between 18 and 60 years old (less than 61 years old)

          -  With newly diagnosed with AML according to WHO classification:

          -  With 20% or more blasts in the bone marrow

          -  Patients with history of tumors other than myeloproliferative disorders or
             myelodysplastic syndromes, having received chemotherapy and/or radiotherapy without
             previous history of myelodysplastic syndromes are eligible for the present study

          -  High-risk cytogenetics defined as one the following abnormalities : 5/5q-, 7/7q-,
             t(6,9), 11q23 abnormality excluding t(9;11), 3q abnormality,complex karyotype (&gt;3
             abnormalites)

          -  Left ventricular ejection fraction (LVEF) &gt; 50% on echocardiography or multigated
             acquisition (MUGA) scan or similar radionuclide angiographic scan.

          -  Adequate liver function (all of the following) except if secondary to the leukemia:

        Total bilirubin below 1.5 x upper limit of normal (ULN), AST and ALT below 2.5 x ULN ,
        gamma-GT below 2.5 x ULN,

          -  Adequate kidney function (all of the following): Serum creatinine below 1.5 x ULN,
             Creatinine clearance above 50 mL/min (Cockroft and Gault formula)

          -  ECOG performance status &lt; or = 2.

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule.

          -  The patient must give written (personally signed and dated) informed consent before
             completing any study-related procedure which means assessment or evaluation that would
             not form part of the normal medical care of the patient.

          -  Affiliated to the French Social Security (Health Insurance).

        Exclusion Criteria:

          -  Previous allogeneic stem cell transplantation.

          -  Pre-existing aplastic anemia

          -  Presence of favourable cytogenetics with t(8;21), t(15;17), or inv(16)

          -  Previous history of MDS or myeloproliferative neoplasm

          -  Uncontrolled active infection.

          -  History of arrythmia.

          -  Cardiac toxicity induced by another anthracycline administration

          -  Maximum cumulative dose reached for any anthracyclin

          -  Allergy to cytarabine, daunorubicin, fish or egg proteins10. Significant neurologic
             (grade &gt; 2) or psychiatric disorder, dementia or seizures.

          -  Clinical symptoms suggesting active central nervous system leukemia.

          -  Degenerative or toxic encephalopathy

          -  Severe complications of leukemia such as:Uncontrolled bleeding, Pneumonia with hypoxia
             or shock

          -  Prior total body irradiation &gt; 10 Gy.

          -  Known active HIV, Hepatitis B or C infection

          -  Pregnancy or breastfeeding

          -  Concomitant anti-amarile vaccination (yellow fever)

          -  Concurrent treatment with any other anti-cancer therapy except Hydroxyurea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel GYAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emmanuel GYAN</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO site</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>high-risk cytogenetics</keyword>
  <keyword>younger patients</keyword>
  <keyword>Induction treatment</keyword>
  <keyword>OMEGAVEN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

